Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

September 30, 2000

Primary Completion Date

November 30, 2003

Study Completion Date

November 30, 2003

Conditions
Myelodysplastic Syndromes
Interventions
BIOLOGICAL

anti-thymocyte globulin

Trial Locations (28)

10021

New York Presbyterian Hospital - Cornell Campus, New York

10029

Mount Sinai Medical Center, NY, New York

10595

New York Medical College, Valhalla

14642

James P. Wilmot Cancer Center, Rochester

20010

Washington Cancer Institute, Washington D.C.

30322

Winship Cancer Institute of Emory University, Atlanta

33136

Sylvester Cancer Center, University of Miami, Miami

33612

Veterans Affairs Medical Center - Tampa (Haley), Tampa

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

46107

Indiana Blood and Marrow Transplant, Beech Grove

60612

Rush Cancer Institute, Chicago

63110

Siteman Cancer Center, St Louis

64111

University of Missouri Kansas City School of Medicine, Kansas City

70112

Tulane University School of Medicine, New Orleans

32610-0296

University of Florida Health Science Center, Gainesville

33612-9497

H. Lee Moffitt Cancer Center and Research Institute, Tampa

52242-1009

Holden Comprehensive Cancer Center, Iowa City

66160-7357

University of Kansas Medical Center, Kansas City

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

63110-2539

Saint Louis University Cancer Center, St Louis

68198-7680

University of Nebraska Medical Center, Omaha

07601

Hackensack University Medical Center, Hackensack

27157-1082

Comprehensive Cancer Center at Wake Forest University, Winston-Salem

75230-2503

Texas Oncology P.A., Dallas

53226-3596

Medical College of Wisconsin, Milwaukee

T2N 2T9

Foothills Hospital, Calgary

V5Z 4E3

Department of Medicine, Vancouver

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00017550 - Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter